HomeQuestion
How do you approach duration of immunotherapy in patients with metastatic NSCLC?
2 Answers
Mednet Member
Medical Oncology · Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center
If someone manages to continue the ICI maintenance up to 2 years without progression, I am comfortable counseling the patient to stop the ICI treatment as per the regulatory approval indication. I have had occasionally, patient's anxiety level driving the desire to continue beyond the 2 years treatm...
Mednet Member
Medical Oncology · University of Texas Health Science Center at Houston
In patients with metastatic NSCLC on immunotherapy without progression at 2 years, I discuss with patients the option of stopping immunotherapy vs continuing it, and then we make a mutual decision in this regard. This is guided by this retrospective review from 2023.